Sana Biotechnology, Inc. is a clinical-stage biotechnology company developing engineered cell and gene therapies. Its work spans ex vivo allogeneic cell therapies using a hypoimmune platform intended to reduce immune rejection, and in vivo gene delivery technologies designed to insert, replace, or control genes in specific cell types. The company’s programs target oncology, genetic, and other serious diseases.
Founded in 2018 and headquartered in Seattle, Washington, Sana operates research and development facilities in the United States, including in the Boston and San Francisco Bay Area biotech hubs. Sana Biotechnology is publicly listed on Nasdaq under the ticker symbol SANA.